Rights and permissions
About this article
Cite this article
Paclitaxel plus cisplatin cost effective in advanced NSCLC. Inpharma Wkly. 1195, 8 (1999). https://doi.org/10.2165/00128413-199911950-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199911950-00015